Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype

Authors:

Abstract
No abstract available
Funding Information
  • Shire Human Genetic Therapies, Inc
  • Shire Human Genetic Therapies
  • Amicus
  • Sanofi Genzyme
  • Shire Human Genetic Therapies
  • Shire Human Genetic Therapies
  • Sanofi Genzyme
  • Sanofi Genzyme

This publication has 30 references indexed in Scilit: